Camlin Fine Sciences Share Price

Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include basic ingredients, aroma ingredients, and health and wellness products comprising algae based products, such as Omega 3 fatty acids. It sells its producrts under the Xtendra, Nasure, Ezential, adorr, Dinamic, and Biosus brands. The company’s products are used in food and beverage, pet food and rendering, animal nutrition, petrochemical, nutrition and health, biofuel, agrochemical, pharmaceutical, polymers, fragrance and flavor, and dyes and pigments industries. The Camlin Fine Sciences share price on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in Camlin Fine Sciences stock pricereveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries..

The Camlin Fine Sciences stock price is shaped by factors including raw material costs, capacity utilisation at its manufacturing plants, global demand for vanillin and antioxidants, and pricing pressures from international competitors. In the longer term, strategies around expanding its blends business, integrating acquisitions, and managing discontinued operations significantly influence market sentiment. All these factors must be closely monitored to have an idea about the Camlin Fine Sciences stock price movements.

Camlin Fine Sciences live share price provides real-time information about Camlin Fine Sciences stock price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring of Camlin Fine Sciences live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Camlin Fine Sciences share͏ price today helps investors understand real-time market sentiment, Camlin Fine Sciences stock pricevolatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Camlin Fine Sciences Limited Company Fundamentals

a. Company Background

Camlin Fine Sciences Limited is an Indian specialty chemicals company engaged in the research, development, manufacture and marketing of chemical‑based solutions that serve diverse industrial sectors including food & beverage, animal nutrition, pet food, petrochemical, health and aroma applications. The company was incorporated on 30 November 1993 and is registered as a public company under the Companies Act, with its registered in Mumbai, Maharashtra, India. It evolved from earlier divisions of the Camlin Group, which began as an inks and stationery products business in the mid‑20th century, and later diversified into fine chemicals in the 1980s. The specialty chemical entity was formally demerged to form Camlin Fine Sciences Ltd. in the mid‑2000s and subsequently listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE).

CFS’s core operations centre on the manufacture of shelf‑life extension solutions (antioxidants), aroma ingredients (such as vanillin), performance chemicals (including hydroquinone and catechol) and health & wellness ingredients. Its product portfolio addresses oxidation control, flavour and fragrance needs, and functional applications in multiple industrial value chains. Camlin Fine Sciences has a turnover of USD 200 million and offers a portfolio of over 100 products. The company employs more than 1,000 professionals and maintains a global sales network spanning 160 locations worldwide.

Over time the company has expanded internationally through subsidiaries and manufacturing facilities in Europe, Latin America and Asia, aiming to serve a global clientele while maintaining integrated production and quality‑focused processes.

b. Company Products

Camlin Fine Sciences (CFS) offers a diversified range of specialty chemical and ingredient products tailored to multiple industrial applications. The company’s portfolio includes:

• Shelf‑Life Solutions / Antioxidants: Traditional and plant‑based antioxidants under the Xtendra® and NaSure™ brands, including TBHQ, BHA, BHT, and ascorbyl palmitate for food, animal nutrition and related industries.

• Functional Ingredients: Ezential™ range of functional excellence ingredients for food and beverage applications.

• Performance Chemicals: Dinamic™ range including hydroquinone, catechol and other diphenols and derivatives serving petrochemicals, pharmaceuticals, polymers, dyes and pigments industries.

• Aroma Ingredients: adorr™ vanillin and ethyl vanillin products produced via vertically integrated processes for flavour and fragrance sectors.

• Health & Wellness Ingredients: Biosus™ DHA and other health‑oriented products from algae‑based sources.

• Specialty Additives: Customised additive blends for niche industrial needs.

c. Company Revenue Model 

Camlin Fine Sciences’ revenue model is centred on the manufacture and sale of specialty chemicals, ingredients and additive solutions across domestic and international markets. Key revenue streams include:

• Product Sales: The principal source of revenue is the sale of shelf‑life solutions (antioxidants), aroma ingredients, performance chemicals and health & wellness products to customers in food & beverage, animal nutrition, petrochemical, pharmaceutical and related sectors.

• B2B Industrial Supply Contracts: Long‑term supply agreements with industrial clients and food manufacturers yield predictable recurring revenue.

• Export & Global Distribution: Sales through international subsidiaries and distributors in Europe, Mexico, Brazil, North America and Asia contribute a substantial portion of exports.

• Value‑Added Blends and Custom Solutions: Revenue is also generated from customised chemical blends and application‑specific ingredient solutions priced at premium levels.

• Brand Licensing & Premium Lines: Proprietary brands such as Xtendra®, NaSure™, Dinamic™, adorr™ and Biosus™ help differentiate offerings and support pricing strategies.

d. Geographic Presence 

Camlin Fine Sciences operates with a substantial global footprint, spanning manufacturing, distribution and sales networks across multiple regions. Its geographic presence includes:

• India (Headquarters & Manufacturing): The company’s headquarters and principal operations are based in Mumbai, with manufacturing facilities and R&D centres, including sites in Dahej SEZ and Tarapur.

• Asia, Middle East & Africa: CFS Pahang Asia Pte. Ltd. in Singapore supports regional distribution and industrial outreach across the Asia Pacific and Middle East markets.

• Europe: Manufacturing and performance chemicals operations in Ravenna, Italy, and corporate offices in Belgium and France bolster its European footprint.

• Americas: Subsidiaries such as CFS do Brasil Ltda. in Brazil and Dresen Química S.A.P.I. de C.V. in Mexico facilitate production and market access in Latin America.

• North America: Presence through distribution and corporate channels in the United States supports global sales, especially for aroma ingredients and antioxidants.

e. Leadership

Some of the key leaders of Camlin Fine Sciences Limited as of February 2026 are:

• Ashish S Dandekar — Chairman & Managing Director

• Nirmal V Momaya — Managing Director

• Arujun S Dukane — Executive Director (Technical)

• Mahabaleshwar G Palekar — Independent Director

• Conrad D Souza — Independent Director

• Pradip M. Kanakia — Independent Director

• Amol Shah — Independent Director

• Anagha S Dandekar — Non‑Executive Director

• Abeezar Faizullabhoy — Independent Director

• Radhika Dudhat — Independent Director

• Harsha Raghavan — Non‑Executive Director

• Rahul Sawale — Vice President & Company Secretary

• Jens Van Nieuwenborgh — Non‑Executive Director

• Mr. Santosh Laxman Parab — Chief Financial Officer

• Neeti Chavan — Senior General Manager, Head (Food Division)

• Nishank Pareek — General Manager (Technical Sales)

• Anvarhusen Bilakhiya — Vice President

• Pankaj Pawade — Senior General Manager (Food Division)

• Rahul Sawale — Company Secretary, Compliance Officer & Vice President (Legal)

f. Key Milestones

• 1931: Original enterprise begins operations in Mumbai focusing on ink powders and stationery products.

• 1984: Diversification into fine chemicals with the establishment of antioxidants manufacturing at Tarapur, India.

• 2006: The fine sciences division is demerged to form Camlin Fine Sciences Ltd. as a separate entity.

• 2007: Camlin Fine Sciences Ltd. is listed on the Bombay Stock Exchange (BSE).

• 2011: Acquisition of Borregaard Italia SpA facility and listing on the National Stock Exchange (NSE).

• 2014: Commencement of operations in Brazil with production of antioxidant blends.

• 2016: Expansion into North America and acquisition of majority stake in Dresen Química in Mexico.

• 2017: Acquisition of stake in Ningbo Wanglong Flavors & Fragrances, enhancing vanillin production.

• 2018: Joint venture in animal nutrition with Pahang Pharma Singapore

g. Industry Perspective

The specialty chemicals industry encompasses a broad range of high‑value chemical products that are formulated for specific performance attributes and end‑use applications such as food additives, antioxidants, aroma chemicals, performance chemicals, coatings, surfactants, and electronic materials. Globally, the specialty chemicals market was estimated at approximately USD 978.97 billion in 2024 and is projected to reach USD 1,312.78 billion by 2030, growing at a compound annual growth rate (CAGR) of about 5 % from 2025 to 2030. This growth reflects rising demand in sectors such as automotive, electronics, pharmaceuticals, construction, and consumer goods, where tailored chemical solutions enhance product performance and functionality. Asia‑Pacific, especially China and India, dominates global production and consumption, driven by rapid industrialisation and expanding manufacturing bases.

In India, the specialty and fine chemicals market was valued at around USD 62.86 billion in 2024 and is expected to grow to about USD 89.20 billion by 2030, with a CAGR of roughly 6 % over 2025‑2030. This faster expansion relative to global growth is linked to India’s cost‑competitive manufacturing, abundant skilled workforce, and diversified end‑use sectors such as automotive, FMCG, agrochemicals, textiles, and pharmaceuticals. Additionally, India’s position in global supply chains is strengthening as companies pursue China+1 diversification strategies and focus on value‑added specialty molecules.

Given the importance of sustainability, regulatory compliance, and technological innovation, the industry is also witnessing increased investment in bio‑based chemicals and eco‑friendly formulations, which are anticipated to shape medium‑ to long‑term growth prospects.

Camlin Fine Sciences Stock Market Presence: Listings & Index Representation

Camlin Fine Sciences Limited listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) after its initial public offering, with shares trading under the scrip code 532834 on BSE and the symbol CAMLINFINE on NSE.

Camlin Fine Sciences Limited is a well-established entity in the Indian stock market, listed on major exchanges such as NSE (CAMLINFINE) and BSE (532834). Its presence in various market indices, including the BSE 1000, BSE Next 250 Microcap, S&P BSE MidSmallCap, S&P BSE SmallCap, S&P BSE Basic Materials, and S&P BSE AllCap, highlights its role within India’s specialty chemicals sector.

The Camlin Fine Sciences share price is tracked by both retail and institutional investors. Its inclusion in these indices reflects its market capitalisation and its position as a player in the speciality chemicals industry. Listing on the NSE and BSE ensures liquidity, while its presence in small and mid-cap indices drives institutional interest and benchmark tracking within the basic materials sector.

Camlin Fine Sciences Stock Performance and Camlin Fine Sciences Share Price History

The Camlin Fine Sciences share price on NSE and BSE reflects its operational journey as a specialty chemical manufacturer. Performance is driven by factors like vanillin realisations, volume growth in the blends segment, integration of acquisitions such as Vinpai, and management of losses from discontinued European and Chinese operations. Investors compare the Camlin Fine Sciences share price today with the Nifty and Sensex to gauge relative performance, especially noting the stock’s underperformance against broader market returns over the past year.

These underlying factors are often visible through real market movements across different periods. Similar trends are observed during earnings-driven movements. Broader sector strength has also played a role, although the Camlin Fine Sciences share price has shown significant negative returns in recent periods, largely due to company-specific challenges. In addition to operational and sector-led factors, corporate actions such as rights issues or strategic restructuring moves can also have a notable impact on the Camlin Fine Sciences share price movements, especially when the company’s financial performance is facing headwinds from discontinued operations.

While short-term movements reflect events and announcements, longer-term valuation trends are visible through the Camlin Fine Sciences share price 52-week high and low, providing context beyond daily or weekly changes. The 52-week high of ₹333.30 and low of ₹110 indicate the wide range of price movement over the past year. Highs were supported by earlier growth expectations, while the recent lows align with the impact of discontinued operations, pricing pressures, and market corrections. These levels capture the effects of operational restructuring, demand fluctuations, and earnings visibility.

Camlin Fine Sciences’ stock performance illustrates the journey of a company navigating growth and operational restructuring. The company’s expansion in blends and focus on vanillin manufacturing have shaped its Camlin Fine Sciences share price history. Over time, the stock has experienced periods of sharp gains and phases of significant decline. The early part of the last decade saw strong growth, but more recent history shows a challenging period.

The data shows that over a 10-year period, the Camlin Fine Sciences share price has delivered a return of 24.76%. However, shorter timeframes tell a different story. The stock has seen a 1-year return of -33.54%, a 3-year return of -11.59%, and a 5-year return of -13.87%. In contrast, over the same periods, the Nifty50 has delivered 37.54% over three years and 62.7% over five years. A 1-day return was -1.16%, while 1-week returns were -13.17%. Over 1 month and 3 months, returns were -20.21% and -26.25% respectively, and over 6 months, the stock fell by -48.68%. The poor 1-year performance, which is worse than the Nifty50, Sensex, industry, and sector, is primarily due to the losses from discontinued operations in Europe and China, pricing pressure from Chinese competitors, and suboptimal capacity utilisation at its vanillin plant.

The Camlin Fine Sciences stock performance over time has been closely tied to the company’s execution of its global strategy. For instance, the Camlin Fine Sciences share price reached a 52-week high above ₹333, supported by investor confidence in its core business growth. However, subsequent declines were driven by operational headwinds, including a major fire at a Brazil blending unit and the ongoing cash burn from discontinued operations. Despite these challenges, the company’s core business has shown resilience, with revenue from continuing operations growing.

Even during periods of broader market volatility, Camlin Fine Sciences shares have been sensitive to company-specific news. While the broader chemical sector faced global headwinds, the company’s prudent management of its core business and strategic moves to exit non-performing units have been key focal points. The company’s performance has been weighed down by exceptional items, such as a provision for embezzlement and impairment losses on investments in subsidiaries, which have significantly impacted net profits.

Camlin Fine Sciences Investor Relevance and Role in Portfolio

Camlin Fine Sciences is considered a niche player in the speciality chemicals sector, offering exposure to the food preservation, animal nutrition, and fragrance ingredient markets. Its role in a portfolio is often tied to its growth potential in the blends business and its position as a major vanillin manufacturer. The company’s focus on value-added products and its global manufacturing footprint make it a relevant consideration for investors focused on the speciality chemicals industry.

The equity of Camlin Fine Sciences is held by a mix of domestic and international institutional investors, reflecting its standing in the speciality chemicals sector. Top institutional stakeholders include Convergent Finance LLP, Ackermans & Van Haaren NV, Infinity Holdings, Infinity Investment Management, Infinity Direct Holdings Sidecar I, ICICI Prudential Asset Management Company Limited, Camart Industries Ltd., Franklin Resources, Inc., Vibha Agencies Pvt Ltd., and Infinity Portfolio Holdings.

Prominent mutual fund holders include ICICI Prudential Mutual Fund’s Commodities Fund, Franklin Templeton Mutual Fund’s India Opportunities Fund, ICICI Prudential Mutual Fund’s Multicap Fund, JM Mutual Fund’s Small Cap Fund, and ICICI Prudential Mutual Fund’s Retirement Fund Pure Equity Plan. International holders include DFA Investment Dimensions Group Inc., SPDR Index Shares Funds, and American Century ETF Trust. This investor base highlights the company’s appeal to funds focused on small and mid-cap companies within the basic materials space.

Beyond fundamentals and ownership, the stock is monitored for its volatility and momentum. Beta values for Camlin Fine Sciences provide insight into its risk profile relative to the market. The long-term beta is 1.69. Over shorter durations, the beta stands at 1.09 for the daily one-month range, 1.69 for the daily three-month range, 3.12 for the weekly one-year range, 2.00 for the weekly two-year range, 1.59 for the two-week two-year range, and 1.56 for the monthly two-year range. The mean stock price over these periods ranges from ₹131.69 to ₹195.01, with standard deviations showing significant volatility. This data indicates that the Camlin Fine Sciences share price tends to be more volatile than the market, particularly over a weekly one-year timeframe.

Camlin Fine Sciences Sectoral Relevance and Peer Positioning

Camlin Fine Sciences sector relevance stems from its scale in manufacturing antioxidants, vanillin, and other specialty chemicals, establishing it as a significant mid-cap player in India’s basic materials ecosystem. Peer comparisons with Vinati Organics, Aarti Industries, Navin Fluorine, Atul Ltd, and Deepak Nitrite focus on product portfolios, capacity utilisation, export competitiveness, and margin profiles rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and global market positioning. Institutional tracking of raw material costs, anti-dumping duties, and global demand for food additives further highlights the company’s importance within India’s broader specialty chemical industry.

Camlin Fine Sciences’ sectoral importance is also reflected in financial and market metrics that demonstrate its scale, stability, and global impact.

Since March 30, 2007, Camlin Fine Sciences’ market cap has increased from 412.25 million to 21.59 billion, a compound annual growth rate of 23.17%. Annual data shows market cap on Mar 24, 2026, was ₹21.76 billion, a 23.63% decline from the previous year. On Dec 31, 2025, it was ₹28.50 billion, reflecting a 29.67% increase from 2024. The market cap was ₹21.98 billion on Dec 31, 2024, down 3.40%, and ₹22.75 billion on Dec 29, 2023, down 9.51%. In 2022, it was ₹25.14 billion (up 51.29%), and in 2021, it stood at ₹16.62 billion (up 6.55%).

On a consolidated basis, Camlin Fine Sciences earnings has grown from ₹1,187.10 crore in Mar-21 to ₹1,666.53 crore in Mar-25. However, net income has turned negative, from a profit of ₹50.96 crore in Mar-21 to a loss of ₹139.05 crore in Mar-25. EBITDA grew from ₹73.51 crore in Mar-19 to ₹212.75 crore in Mar-25. The loss after tax for FY 2024-25 was ₹15,811.94 lakh, driven by a ₹20,752.39 lakh loss from discontinued operations. The company’s core business remains profitable, with profit from continuing operations before tax at ₹5,884.40 lakh.

Camlin Fine Sciences EPS has shown a negative trend in recent years. On a consolidated adjusted basis, EPS was ₹3.91 in Mar-21, ₹3.78 in Mar-22, ₹3.24 in Mar-23, -₹5.41 in Mar-24, and -₹7.40 in Mar-25. The latest EPS for the period ending Mar-25 is -₹7.40, continuing the negative trend from the previous year. The year-on-year change shows a decline of 14.29% in Mar-23, -3.32% in Mar-22, and significant negative figures in the last two years due to exceptional losses.

Camlin Fine Sciences P/E ratio is currently negative due to negative EPS. The P/E ratio was 36.94 in Mar-23, 29.99 in Mar-22, 35.14 in Mar-21, and 15.60 in Mar-20. It turned negative in Mar-24 at -15.99 and further declined to -20.89 in Mar-25, a -30.61% change. The trailing twelve months P/E is -33.66. The latest P/E ratio of -20.89 is lower than the average P/E of 13.04 over the last five years, indicating the impact of recent financial losses on market valuation.

Finally, Camlin Fine Sciences’ long-term earnings trajectory demonstrates its operational scale. Statutory financial disclosures show revenue rising from ₹47.03 crore in 2007 to over ₹1,666 crore in 2025. However, earnings have been volatile, with net income declining in recent years due to exceptional items and discontinued operations. These trends reflect the challenges and strategic shifts the company has been navigating within the global specialty chemicals landscape.

Summary

Camlin Fine Sciences is a speciality chemical manufacturer with a significant global presence in antioxidants and vanillin. Its recent financial performance reflects challenges from discontinued operations and pricing pressures, even as its core business shows growth. The Camlin Fine Sciences share price has experienced high volatility, underperforming the broader market over the past year. The company’s future remains tied to the successful execution of its strategic plans.